Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.

Emma L SimpsonShijie RenEmma S HockJohn W StevensAymeric BinardYves-Marie PersRachel ArcherSuzy PaisleyMatthew D StevensonChloé HerpinSalah Ghabri

Published in: International journal of technology assessment in health care (2019)

In MTX-naïve patients, there was insufficient evidence that combination boDMARDs was superior to two or more csDMARDs. In csDMARD-experienced patients, boDMARDs and bsDMARDs were comparable and all combination boDMARDs / bsDMARDs were superior to single csDMARD.

Keyphrases

rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells
mesenchymal stem cells
bone marrow